Overview

Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin.
Phase:
Phase 4
Details
Lead Sponsor:
Michael Mann
Collaborator:
Sanofi
Treatments:
Carboplatin
Docetaxel